Sugi Predict

Sugi Predict / Targets / TP53

TP53

Cellular tumor antigen p53 · P04637 · TP53 on Sugi Atlas →

2,209,112 patent compounds predicted against TP53, 1,294,566 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7918 SCHEMBL7918 0.52 10/20
SCHEMBL7038 SCHEMBL7038 0.49 8/20
SCHEMBL7084 SCHEMBL7084 0.49 8/20
SCHEMBL6900 SCHEMBL6900 0.64 7/20
SCHEMBL7842 SCHEMBL7842 0.49 7/20
SCHEMBL7515 SCHEMBL7515 0.46 7/20
Chlorpromazine Chlorpromazine (SCHEMBL8321) 1.00 6/20
SCHEMBL7334 SCHEMBL7334 0.59 6/20
SCHEMBL7312 SCHEMBL7312 0.56 5/20
SCHEMBL1672 SCHEMBL1672 0.54 5/20
SCHEMBL7172 SCHEMBL7172 0.53 5/20
SCHEMBL7046 SCHEMBL7046 0.52 5/20
SCHEMBL584 SCHEMBL584 0.51 5/20
SCHEMBL6648 SCHEMBL6648 0.50 5/20
SCHEMBL8988 SCHEMBL8988 0.49 5/20
SCHEMBL7724 SCHEMBL7724 0.48 5/20
SCHEMBL8159 SCHEMBL8159 0.46 5/20
SCHEMBL6254 SCHEMBL6254 0.44 5/20
Chloroxine Chloroxine (SCHEMBL3350) 1.00 4/20
Iodoquinol Iodoquinol (SCHEMBL3460) 1.00 4/20

Clinical trials — most relevant to TP53 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation PHASE2UNKNOWN
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer PHASE2RECRUITING
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. PHASE2UNKNOWN
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery PHASE2RECRUITING
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma PHASE1/PHASE2COMPLETED
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease PHASE2RECRUITING
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer PHASE1/PHASE2COMPLETED
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer PHASE2COMPLETED
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer PHASE2COMPLETED
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations PHASE2UNKNOWN
Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer PHASE1/PHASE2COMPLETED
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) PHASE1RECRUITING
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies PHASE1COMPLETED
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors PHASE1SUSPENDED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Vaccine Therapy in Treating Patients With Head and Neck Cancer PHASE1COMPLETED
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy PHASE1ACTIVE_NOT_RECRUITING
Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed PHASE1COMPLETED
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies PHASE1RECRUITING
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation PHASE1RECRUITING
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor EARLY_PHASE1NOT_YET_RECRUITING
Advanced Refractory Solid Tumors With TP53 Mutations Register Study nanUNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma nanCOMPLETED
Biomarker Monitoring in TP53 Mutation Carriers nanCOMPLETED
Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53 nanUNKNOWN
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN
Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation nanUNKNOWN
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TP53 binder may also engage these)

ProteinNameSimilarity
P61260 — 1.000 P61260 →
P56424 — 1.000 P56424 →
Q9TTA1 — 1.000 Q9TTA1 →
Q9TUB2 — 1.000 Q9TUB2 →
P56423 — 1.000 P56423 →
P13481 — 1.000 P13481 →
O36006 — 1.000 O36006 →
Q29537 — 1.000 Q29537 →
P67938 — 1.000 P67938 →
Q95330 — 1.000 Q95330 →
O09185 — 1.000 O09185 →
P41685 — 1.000 P41685 →
P67939 — 1.000 P67939 →
P10361 — 1.000 P10361 →
Q00366 — 1.000 Q00366 →
P51664 — 1.000 P51664 →
P79734 — 1.000 P79734 →
P25035 — 1.000 P25035 →
O93379 — 1.000 O93379 →
Q64662 — 1.000 Q64662 →
Q8SPZ3 — 1.000 Q8SPZ3 →
P79892 — 1.000 P79892 →
P02340 — 1.000 P02340 →
Q9WUR6 — 0.999 Q9WUR6 →
P10360 — 0.999 P10360 →
O57538 — 0.998 O57538 →
Q92143 — 0.998 Q92143 →
P79820 — 0.997 P79820 →
Q9W679 — 0.996 Q9W679 →
P07193 — 0.994 P07193 →